Dr Nathaniel Dasyam is a postdoctoral researcher who has been working in the Malaghan Institute\u2019s CAR T-cell therapy programme since 2019. Nathaniel is a self-described \u2018Jack of all trades\u2019 when it comes to his role within the programme..<\/p>\n
Nathaniel works in the research team, where the CAR T-cells are designed, and supports both the GMP team, where the CAR T-cells are manufactured, and the clinical team, who administer the CAR T-cells to participants in the trial.<\/p>\n
\u201cIt just so happened that the project I was working on previously at the Malaghan Institute, to test a therapeutic vaccine for melanoma, laid the groundwork for many of the processes that needed to be in place to manufacture CAR T-cells.\u201d<\/p>\n
This placed Nathaniel in an ideal position to help the CAR T-cell team develop methods needed to test CAR T-cells for the ENABLE clinical trial \u2013 a first of this kind for New Zealand. This was no mean feat given it involves developing a gene therapy in a highly regulated environment.<\/p>\n
CAR T-cell therapy works by extracting a patient\u2019s own immune cells and modifying them in the lab to identify and attack cancer cells once they have been returned to the patient. The ENABLE trial uses CAR T-cells to treat patients with certain types of relapsed and refractory B-cell non-Hodgkin lymphoma, who have exhausted other treatment options. Read more here:\u00a0first-car-t-cell-therapy-clinical-trial<\/a><\/p>\n <\/p>\n","protected":false},"excerpt":{"rendered":" Dr Nathaniel Dasyam is a postdoctoral researcher who has been working in the Malaghan Institute\u2019s CAR T-cell therapy programme since […]<\/p>\n","protected":false},"author":2,"featured_media":19228,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"image","meta":{"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[12,17],"tags":[26,30,31],"class_list":["post-19227","post","type-post","status-publish","format-image","has-post-thumbnail","hentry","category-news-media","category-featured","tag-chronic-lymphocytic-leukaemia","tag-blood-cancer","tag-cll-advocates","post_format-post-format-image"],"jetpack_featured_media_url":"https:\/\/clladvocates.nz\/wp-content\/uploads\/2023\/03\/Car_T_Cell.jpg","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/clladvocates.nz\/index.php?rest_route=\/wp\/v2\/posts\/19227","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clladvocates.nz\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/clladvocates.nz\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/clladvocates.nz\/index.php?rest_route=\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/clladvocates.nz\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=19227"}],"version-history":[{"count":1,"href":"https:\/\/clladvocates.nz\/index.php?rest_route=\/wp\/v2\/posts\/19227\/revisions"}],"predecessor-version":[{"id":19229,"href":"https:\/\/clladvocates.nz\/index.php?rest_route=\/wp\/v2\/posts\/19227\/revisions\/19229"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/clladvocates.nz\/index.php?rest_route=\/wp\/v2\/media\/19228"}],"wp:attachment":[{"href":"https:\/\/clladvocates.nz\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=19227"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/clladvocates.nz\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=19227"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/clladvocates.nz\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=19227"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}